Veritas In Silico Inc 130A
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥338.00
- Day Range
- ¥364.00–418.00
- 52-Week Range
- ¥331.00–793.00
- Bid/Ask
- ¥418.00 / ¥0.00
- Shares Outstanding
- 6.49M
- Market Cap
- ¥2.71B
- Volume/Avg
- 621,200 / 32,444
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 32.12
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs. The company operates a pipeline-type business model, currently focuses on nucleic acid drugs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 19
- Website
- https://www.veritasinsilico.com
Valuation
|
Metric
|
130A
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.94 |
Price/Sales | 32.12 |
Price/Cash Flow | — |
Price/Earnings
130A
Financial Strength
|
Metric
|
130A
|
|---|---|
Quick Ratio | 15.73 |
Current Ratio | 16.46 |
Interest Coverage | — |
Quick Ratio
130A
Profitability
|
Metric
|
130A
|
|---|---|
Return on Assets (Normalized) | −26.77% |
Return on Equity (Normalized) | −28.59% |
Return on Invested Capital (Normalized) | −28.80% |
Return on Assets
130A
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!GpSVy< | LOCK|^q?!% | $127B | |||
| Moderna Inc
MRNA
| LOCK|fL&&c!S | LOCK|gxW | $91B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|s<#&rR | LOCK|&BbH< | $81B | |||
| argenx SE ADR
ARGX
| LOCK|?%<$?& | LOCK|>%m | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|lLR%?> | LOCK|c& | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|NhQz^!M | LOCK|KSj#> | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|D<&>#>$& | LOCK|&h<b | $27B | |||
| Incyte Corp
INCY
| LOCK|^Jd^Kc | LOCK|>dN | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^$b$$q | LOCK|?N | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&XG%Nr | LOCK|l#M | $14B |
United States